ublituximab
ublituximab is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including BRIUMVI. Available dosage forms: solution, injection, solution, concentrate, liquid.
Drug Details
- Generic Name
- ublituximab
- Brand Names
- BRIUMVI
- Application Number
- BLA761238
- Sponsor
- Samsung BioLogics Co. LTD
- NDC Codes
- 3
- Dosage Forms
- SOLUTION, INJECTION, SOLUTION, CONCENTRATE, LIQUID
- Routes
- INTRAVENOUS
- Active Ingredients
- UBLITUXIMAB, UBLITUXIMAB-XIIY
Indications and Usage
1 INDICATIONS AND USAGE BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BRIUMVI is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 , 14 ).